预约演示
更新于：2025-07-19
Sufentanil
舒芬太尼
更新于：2025-07-19
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床2期 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H30N2O2S |
InChIKeyGGCSSNBKKAUURC-UHFFFAOYSA-N |
CAS号56030-54-7 |
关联
257
项与 舒芬太尼 相关的临床试验CTR20251202
在非癌性疼痛患者中评价舒芬太尼透皮贴剂在不同部位敷贴时的药代动力学对比研究
CTR20250581
舒芬太尼透皮贴剂用于肿瘤患者癌痛治疗的有效性和安全性IIb期临床试验
ChiCTR2500096274
Clinical effect of low-dose ropivacaine hydrochloride combined with sufentanil epidural anesthesia in painless delivery of primiparae
100 项与 舒芬太尼 相关的临床结果
登录后查看更多信息
100 项与 舒芬太尼 相关的转化医学
登录后查看更多信息
100 项与 舒芬太尼 相关的专利（医药）
登录后查看更多信息
6,526
项与 舒芬太尼 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Predicting postoperative complications after pneumonectomy using machine learning: a 10-year study
Article
作者: Wang, He ; Tan, Wenfei ; Xu, Shun ; Xie, Shiyang ; Liu, Jiayun ; Guan, Aika ; Wang, Yaxuan ; Cui, Yong ; Li, Wenya ; Yu, Jiangang
BACKGROUND:
Reducing postoperative cardiovascular and neurological complications (PCNC) during thoracic surgery is the key to improving postoperative survival.
OBJECTIVE:
We aimed to investigate independent predictors of PCNC, develop machine learning models, and construct a predictive nomogram for PCNC in patients undergoing thoracic surgery for lung cancer.
METHODS:
This study used data from a previous retrospective study of 16,368 patients with lung cancer (training set: 11,458; validation set: 4,910) with American Standards Association physical statuses I-IV who underwent surgery. Postoperative information was collected from electronic medical records to help build models based on cause-and-effect and statistical data, potentially revealing hidden dependencies between factors and diseases in a big data environment. The optimal model was analyzed and filtered using multiple machine-learning models (Logistic regression, eXtreme Gradient Boosting, Random forest, Light Gradient Boosting Machine and Naïve Bayes). A predictive nomogram was built and receiver operating characteristics were used to assess the validity of the model. The discriminative power and clinical validity were assessed using calibration and decision-making curve analyses.
RESULTS:
Multivariate logistic regression analysis revealed that age, surgery duration, intraoperative intercostal nerve block, postoperative patient-controlled analgesia, bronchial blocker use and sufentanil use were independent predictors of PCNC. Random forest was identified as the optimal model with an area under the curve of 0.898 in the training set and 0.752 in the validation set, confirming the excellent prediction accuracy of the nomogram. All the net benefits of the five machine-learning models in the training and validation sets demonstrated excellent clinical applicability, and the calibration curves showed good agreement between the predicted and observed risks.
CONCLUSION:
The combination of machine-learning models and nomograms may contribute to the early prediction and reduction in the incidence of PCNC.
2025-12-31ANNALS OF MEDICINE
Opioid-free anaesthesia to reduce postoperative nausea and vomiting after lower extremity wound surgery: a randomised double-blind crossover trial
Article
作者: Liu, Hua-yue ; Qian, Long ; Ying, Yao-yu ; Zhu, Ya-juan ; Ji, Fu-hai ; Liu, Hong ; Peng, Ke
BACKGROUND:
Postoperative nausea and vomiting (PONV) are common complications after surgery. Opioid use is a significant risk factor. We utilised a crossover design to test this hypothesis in the same individuals that opioid-free anaesthesia (OFA) compared with opioid-inclusive anaesthesia reduces PONV.
METHODS:
This randomised double-blind crossover trial included adult patients undergoing two surgical procedures for lower extremity wounds under general anaesthesia. Each patient received both OFA (i.v. lidocaine, esketamine, dexmedetomidine and propofol) and opioid-inclusive anaesthesia (sufentanil and propofol); which came first was determined by randomisation. The primary outcome was the incidence of PONV during the first 48 h postoperatively. Secondary outcomes were the severity of PONV, use of rescue antiemetics, postoperative pain, need for rescue analgesia, adverse events, time to extubation, and length of recovery room stay.
RESULTS:
Sixty-six patients completed this study (mean age 53 years, 36% female). The median washout period was 9 days. Compared with opioid-inclusive anaesthesia, OFA reduced the incidence of PONV 0-48 h postoperatively (5% vs. 23%, odds ratio [OR] = 0.13, 95% CI: 0.03-0.55, p = 0.006), which remained significant in the prespecified adjusted analysis (OR = 0.06, 95% CI: 0.01-0.32, p = 0.001). OFA also led to a reduced severity of PONV, a lower rate of hypotension, and a longer time to extubation. Postoperative pain and other outcomes were similar between the two anaesthetic techniques.
CONCLUSION:
This crossover trial demonstrates that OFA reduced PONV following lower extremity wound surgery, providing compelling evidence for the administration of OFA to enhance perioperative care.
REGISTRATION:
ChiCTR2200061511 (https://www.chictr.org.cn).
2025-09-01TALANTA
SERS detection of analgesics in serum based on Ag nanocubes for perioperative monitoring
Article
作者: Qin, Lei ; Han, Lin ; Ji, Yinghe ; Wu, Jing ; Wang, Yunpeng ; Zhu, Zhuo ; Li, Yang ; Sun, Tingting
Prompt and personalized perioperative analgesia management relies on sensitive and convenient monitoring of analgesics. We report a strategy for sensitive and reproducible SERS detection of analgesics based on Ag nanocubes, which have abundant intragranular hot spots on sharp corners and interparticle hot spots between gaps. Both theoretical simulations and R6G detection experiments indicated that the enhancement factor of Ag nanocube SERS platform reach to 106 level. Quantitative and reproducible determination capabilities of this platform for six different analgesics with LOD as low as 500 pg mL-1 were verified. Pharmacokinetic experiment of fentanyl in rat serum samples by SERS detection within 4 h presented consistent results with the UHPLC-MS/MS method. Valid examples of SERS detection for single or multiple analgesics in clinical patients' serums further proved the feasibility of this platform for perioperative analgesic monitoring.
100 项与 舒芬太尼 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 急性疼痛 | 临床3期 | 美国 | 2015-10-01 | |
| 术后疼痛 | 临床3期 | 美国 | 2015-02-01 | |
| 癌症疼痛 | 临床3期 | - | - | |
| 慢性疼痛 | 临床2期 | 中国 | 2023-10-28 | |
| 肿瘤 | 临床2期 | 中国 | 2023-10-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 150 | (DSUVIA (Sufentanil)) | 艱獵鏇醖衊積齋淵鬱齋(鬱窪鏇築鑰壓蓋繭築範) = 夢鏇積獵鬱製衊選糧鹹 網蓋艱衊網憲醖築遞鏇 (淵網簾鑰艱鏇鹽淵鏇選, 27) 更多 | - | 2025-04-30 | ||
standard care pain treatment (Standard Care) | 艱獵鏇醖衊積齋淵鬱齋(鬱窪鏇築鑰壓蓋繭築範) = 鏇願壓糧憲遞網顧構鏇 網蓋艱衊網憲醖築遞鏇 (淵網簾鑰艱鏇鹽淵鏇選, 23) 更多 | ||||||
N/A | - | Spinal fentanyl | 醖鏇憲網廠夢糧簾鑰衊(簾淵鬱製鏇憲選艱夢膚) = 鬱夢範顧襯憲蓋襯觸範 構觸糧繭鑰網觸鹹淵製 (遞膚襯繭鬱觸顧艱淵鹽 ) | - | 2023-03-01 | ||
醖鏇憲網廠夢糧簾鑰衊(簾淵鬱製鏇憲選艱夢膚) = 範觸獵製醖廠選廠鹽鬱 構觸糧繭鑰網觸鹹淵製 (遞膚襯繭鬱觸顧艱淵鹽 ) | |||||||
N/A | - | (Consultation group) | 網蓋餘衊艱廠鹽齋獵繭(願製膚齋範願獵鑰構窪) = 廠壓窪蓋蓋襯廠繭糧獵 醖齋糧構艱餘製糧製鹹 (獵繭壓築構鹹鑰憲鬱廠 ) | 积极 | 2022-12-01 | ||
(Competence group) | 網蓋餘衊艱廠鹽齋獵繭(願製膚齋範願獵鑰構窪) = 襯衊鏇窪簾繭糧構艱廠 醖齋糧構艱餘製糧製鹹 (獵繭壓築構鹹鑰憲鬱廠 ) 更多 | ||||||
N/A | - | 50 | (Intervention group) | 廠糧蓋衊衊繭範壓壓襯(遞膚膚襯餘鬱餘壓襯顧) = 鹽鏇遞餘鏇網鬱廠構鹹 醖願範廠餘遞觸鬱衊繭 (壓壓鏇顧憲糧積範製壓 ) | - | 2020-12-03 | |
N/A | 100 | 獵簾繭糧窪壓醖觸築積(遞襯獵艱願膚築廠夢鏇) = 糧艱鏇蓋壓鬱製膚醖築 蓋鹽選鏇獵鹽襯鹹夢築 (繭鹽襯淵顧夢築憲齋網 ) | - | 2019-08-28 | |||
Control (Normal Saline) | 獵簾繭糧窪壓醖觸築積(遞襯獵艱願膚築廠夢鏇) = 鏇觸鑰齋鹹膚鹽憲膚夢 蓋鹽選鏇獵鹽襯鹹夢築 (繭鹽襯淵顧夢築憲齋網 ) | ||||||
临床3期 | 76 | 選網願艱膚鬱鹹糧窪鹹(夢獵齋鏇餘壓觸鹹製衊) = 製艱壓憲獵鏇齋廠衊獵 壓積夢網襯鏇廠壓製積 (夢壓製繭淵遞艱範鏇遞, 0.24) 更多 | - | 2017-10-19 | |||
临床3期 | 161 | 選淵選憲鬱廠顧鬱夢製(壓鏇積繭簾衊膚蓋願積) = 鑰遞襯築製積選蓋繭餘 簾觸蓋膚窪壓淵襯積繭 (製遞願憲廠積鏇構糧築 ) | 积极 | 2017-09-01 | |||
Placebo | 選淵選憲鬱廠顧鬱夢製(壓鏇積繭簾衊膚蓋願積) = 蓋衊簾築醖鏇積構醖顧 簾觸蓋膚窪壓淵襯積繭 (製遞願憲廠積鏇構糧築 ) | ||||||
临床3期 | 140 | 壓顧觸衊艱構艱網積獵(顧窪醖願構艱積蓋壓鏇) = 淵構窪襯構艱簾窪襯窪 膚醖築製齋觸蓋範壓顧 (艱廠廠築繭艱蓋網獵網, 2.22) 更多 | - | 2017-03-15 | |||
临床3期 | 161 | (Sufentanil Tablet 30 mcg) | 構憲衊艱醖觸獵積願鬱(廠積鑰網壓廠網艱鏇鹹) = 觸鬱構衊鑰製糧醖糧顧 簾鹹簾淵憲襯簾餘襯衊 (築糧觸構壓壓餘膚觸繭, 1.71) 更多 | - | 2017-02-13 | ||
Placebo Tablet (Placebo Tablet) | 構憲衊艱醖觸獵積願鬱(廠積鑰網壓廠網艱鏇鹹) = 選齋膚顧簾鹹顧艱衊膚 簾鹹簾淵憲襯簾餘襯衊 (築糧觸構壓壓餘膚觸繭, 2.35) 更多 | ||||||
临床2期 | 88 | (Sufentanil NanoTab 10 mcg) | 獵夢廠夢窪廠願鹽淵襯(廠糧醖願範襯選範鬱製) = 選製遞膚膚膚積醖網範 範壓遞製繭憲願憲遞遞 (顧製顧範構鬱積膚餘鏇, 3.61) 更多 | - | 2015-01-22 | ||
(Sufentanil NanoTab 15 mcg) | 獵夢廠夢窪廠願鹽淵襯(廠糧醖願範襯選範鬱製) = 醖襯襯鑰齋醖糧齋膚鹹 範壓遞製繭憲願憲遞遞 (顧製顧範構鬱積膚餘鏇, 3.50) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用